

Frederik Holst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5233183/publications.pdf>

Version: 2024-02-01

23
papers

1,219
citations

516710

16
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

2442
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 334-345.	7.0	17
2	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. <i>Scientific Reports</i> , 2017, 7, 10240.	3.3	19
3	Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 432.e1-432.e17.	1.3	38
4	ESR1 -Amplification-Associated Estrogen Receptor Activity in Breast Cancer. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 751-752.	7.1	8
5	Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. <i>Scientific Reports</i> , 2016, 6, 25521.	3.3	13
6	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. <i>Nature Genetics</i> , 2016, 48, 848-855.	21.4	174
7	Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate. <i>World Journal of Clinical Oncology</i> , 2016, 7, 160.	2.3	21
8	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. <i>Oncotarget</i> , 2015, 6, 1327-1339.	1.8	50
9	Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. <i>Gynecologic Oncology</i> , 2014, 134, 599-606.	1.4	8
10	Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 745-753.	2.5	41
11	High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition. <i>Clinical Cancer Research</i> , 2013, 19, 2331-2341.	7.0	35
12	Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers. <i>PLoS ONE</i> , 2013, 8, e54873.	2.5	70
13	ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous. <i>PLoS ONE</i> , 2013, 8, e84189.	2.5	14
14	KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. <i>British Journal of Cancer</i> , 2012, 107, 1997-2004.	6.4	68
15	Role of cyclin D1 amplification and expression in vulvar carcinomas. <i>Human Pathology</i> , 2012, 43, 1386-1393.	2.0	16
16	On the evidence for ESR1 amplification in breast cancer. <i>Nature Reviews Cancer</i> , 2012, 12, 149-149.	28.4	17
17	Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 10501-10501.	1.6	3
18	<i>PPF1A1</i> and <i>CCND1</i> are frequently coamplified in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 1-8.	2.8	20

#	ARTICLE	IF	CITATIONS
19	Estrogen receptor gene amplification occurs rarely in ovarian cancer. <i>Modern Pathology</i> , 2009, 22, 191-196.	5.5	20
20	Oestrogen receptor gene (<i>ESR1</i>) amplification is frequent in endometrial carcinoma and its precursor lesions. <i>Journal of Pathology</i> , 2008, 216, 151-157.	4.5	35
21	Reply to "ESR1 gene amplification in breast cancer: a common phenomenon?" <i>Nature Genetics</i> , 2008, 40, 810-812.	21.4	47
22	Estrogen receptor alpha (<i>ESR1</i>) gene amplification is frequent in breast cancer. <i>Nature Genetics</i> , 2007, 39, 655-660.	21.4	351
23	Genetic Association of a Cystatin C Gene Polymorphism With Late-Onset Alzheimer Disease. <i>Archives of Neurology</i> , 2000, 57, 1579.	4.5	134